Tumor Necrosis Factor Inhibitor Drugs Market Analysis

Drug Class (Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab Pegol)

Adalimumab segment is expected to account for tumor necrosis factor inhibitor drugs market share of more than 56.3% by the end of 2037 owing to its broad application in the treatment of autoimmune illnesses, safety record, and broad efficacy. Better clinical trial outcomes, a wide range of indications, and great patient and physician familiarity are all factors contributing to the segment's growth. tumor necrosis factor inhibitor drugs market share is also increased by the continuous development of novel formulations and delivery systems.

Furthermore, adalimumab is the first and only fully human monoclonal antibody approved by the U.S FDA for the treatment of rheumatoid arthritis, used to treat a variety of inflammatory conditions in adults and children, including those brought on by autoimmune diseases. In July 2023, Sandoz announced the launch of Hyrimoz, the only adalimumab HCF biosimilar approved in the U.S.

Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s disease, Psoriasis, Ulcerative colitis, Ankylosing spondylitis, Juvenile idiopathic arthritis, Hidradenitis Suppurativa)

In tumor necrosis factor inhibitor drugs market, rheumatoid arthritis segment is set to dominate revenue share of over 42.8% by 2037 owing to the rising prevalence of rheumatoid arthritis across the globe and rising product launches. As per a study by Research Nester, over 350 million individuals worldwide were estimated to have arthritis in 2021 and this number is projected to rise due to several factors, including the growing global burden of the aging population. Adalimumab, infliximab, and etanercept are examples of TNF inhibitors that are very successful in treating RA symptoms and delaying the course of the illness.

Due to their robust clinical performance and excellent safety records, biologic medications are now the mainstay of RA treatment. For example, in December 2019, Amgen announced that its AVSOLA for moderate-to-severe rheumatoid arthritis received U.S. FDA approval.

Our in-depth analysis of the tumor necrosis factor inhibitor drugs market includes the following segments